Meeting
2023 ASCO Annual Meeting
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.
Presenter
Benjamin Besse, MD, PhD
Gustave Roussy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
New Partners for EGFR-Mutant Lung Cancer
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04077463
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9013)
DOI
10.1200/JCO.2023.41.16_suppl.9013
Abstract #
9013
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
Speaker: Natasha B. Leighl, MD, FASCO
Videos & Slides
2024 ASCO Annual Meeting
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2.
Speaker: Byoung Chul Cho, MD, PhD
Videos & Slides
2024 ASCO Annual Meeting
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
Speaker: Enriqueta Felip, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.
Speaker: Catherine A. Shu, MD